Mycoplasma Detection Kit Market Overview
The mycoplasma detection kit market size is expected to grow from USD 5437.38 million in 2025 to USD 5921.31 million in 2026 and is forecast to reach USD 12009.05 million by 2035 at 8.9% CAGR over 2026-2035.
The Mycoplasma Detection Kit Market is gaining importance as pharmaceutical manufacturers, healthcare laboratories, biotechnology companies, and research organizations strengthen their efforts to identify mycoplasma contamination in biological samples and cell-based production environments. Mycoplasmas are small bacteria that lack a cell wall and can contaminate cell cultures without producing immediately visible changes in laboratory conditions. Their presence can alter cellular metabolism, gene expression, growth characteristics, and experimental outcomes, making reliable detection essential for maintaining biological product quality. Mycoplasma testing is particularly important in vaccine manufacturing, biologics development, cell culture operations, and advanced therapeutic research. Traditional microbiological procedures can require approximately 28 days to complete, whereas validated nucleic acid amplification techniques can produce results within several hours. This difference is encouraging laboratories to adopt faster detection technologies alongside established testing procedures. Colloidal Gold Type and Enzyme Linked Immunosorbent products address different testing requirements, including rapid screening and antigen-based detection.
The United States represents a significant geographical market because of its established pharmaceutical manufacturing industry, extensive biotechnology research infrastructure, and stringent expectations for biological product quality. Manufacturers of vaccines, cell-based therapeutics, and biological medicines must maintain appropriate contamination monitoring procedures throughout production and quality control operations. Mycoplasma contamination can compromise an entire cell culture batch, creating substantial operational and regulatory concerns for manufacturers. Testing institutions and specialized laboratories therefore require dependable detection kits capable of supporting routine screening and confirmatory investigations. The regulatory framework for biological products includes established expectations for mycoplasma testing, with traditional compendial culture methods requiring extended observation periods of up to 28 days. Faster analytical methods are attracting interest because they can improve production monitoring and shorten investigation timelines when appropriately validated. Hospitals and clinics also require reliable diagnostic testing capabilities for selected clinical investigations, although specialized pharmaceutical and biotechnology quality control remains an important source of commercial demand. Continued investment in biological manufacturing, advanced cell therapies, and laboratory testing infrastructure is expected to support the United States market throughout the 2026–2035 period.
Download Free sample to learn more about this report.
Key Findings
- Leading Product Type: Enzyme Linked Immunosorbent is projected to lead product demand with an estimated 57% share, supported by established immunoassay workflows and suitability for screening multiple biological samples.
- Leading Application: Testing Institutions are expected to dominate application demand with approximately 46% share, reflecting specialized contamination testing, quality assurance, and routine biological sample evaluation.
- Leading Region: North America is projected to lead with 34% regional share, supported by extensive biotechnology manufacturing, pharmaceutical quality control, and established laboratory testing infrastructure.
- Fastest Growing Region: Asia-Pacific is anticipated to record the fastest expansion at a projected 10.7% CAGR during 2026–2035, driven by increasing biopharmaceutical production capacity.
- Technology Trend: Rapid molecular detection is reshaping testing workflows, with validated nucleic acid amplification procedures capable of delivering results within approximately 3 hours.
- Market Driver: Increasing contamination-control requirements are strengthening demand, as conventional compendial mycoplasma culture testing can require up to 28 days of observation.
- Competitive Landscape: Manufacturers are expanding rapid testing capabilities, with molecular screening platforms increasingly supporting detection across more than 100 recognized mycoplasma species and strains.
- Future Outlook: The market is projected to achieve 8.9% CAGR between 2026 and 2035, supported by expanding biologics manufacturing and increasingly rigorous contamination monitoring.
Latest Trends
The Mycoplasma Detection Kit Market is increasingly influenced by rapid molecular testing, improved immunoassay sensitivity, and the integration of contamination monitoring into modern biological manufacturing workflows. Pharmaceutical and biotechnology organizations are placing greater emphasis on identifying contamination before it affects large-scale cell culture operations or biological product batches. Polymerase chain reaction-based methods are gaining importance because they can detect mycoplasma genetic material without waiting for visible microbial growth. Validated molecular assays can provide results within approximately 3 hours, compared with traditional culture procedures that may require 28 days of observation. This difference is particularly relevant for manufacturers operating continuous or time-sensitive production processes. At the same time, enzyme-linked immunosorbent assay platforms remain relevant for laboratories requiring established antigen-based testing procedures and standardized immunological workflows. Colloidal Gold Type products are attracting attention for their convenient rapid-screening characteristics, particularly where straightforward sample processing and visual result interpretation are important. Improvements in reagent stability, assay specificity, detection limits, and standardized controls are encouraging manufacturers to develop testing products suited to different laboratory environments.
Another important trend involves the increasing adoption of risk-based contamination monitoring and alternative microbiological testing methods across the pharmaceutical and biotechnology industries. Cell and gene therapy manufacturing, recombinant protein production, and vaccine development require reliable monitoring of biological starting materials, intermediate products, and finished preparations. As production processes become more complex, laboratories are evaluating methods that combine rapid detection with appropriate validation and documentation. International pharmaceutical quality standards increasingly emphasize scientifically justified testing procedures, method suitability, and reliable contamination control. Quantitative PCR, real-time PCR, and other nucleic acid amplification technologies are being incorporated into laboratory workflows to improve detection speed and analytical sensitivity. Automated sample preparation and integrated analytical platforms are also reducing manual handling requirements. These developments are influencing the design of immunoassay and rapid-screening products, while specialized testing institutions are expanding their analytical service capabilities. The growing importance of advanced biologics and cell-based production is expected to strengthen demand for reliable mycoplasma detection solutions across multiple applications.
Market Dynamics
Driver
"Increasing emphasis on contamination control in biological manufacturing."
The Mycoplasma Detection Kit Market is primarily driven by the growing need to maintain contamination-free biological production environments. Mycoplasmas can enter cell culture systems through contaminated raw materials, laboratory reagents, biological samples, personnel handling, and inadequately controlled equipment. Unlike many conventional bacterial contaminants, these organisms may not produce obvious turbidity or visible changes in culture media. Their presence can therefore remain undetected until cellular characteristics or manufacturing outcomes are affected. Pharmaceutical manufacturers require effective testing procedures to identify contamination before it compromises production batches. Conventional compendial culture methods can require up to 28 days of incubation and observation, creating demand for faster screening technologies that can complement established quality control procedures.
The expansion of biologics manufacturing is strengthening this requirement. Monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapeutic products depend on controlled biological production systems in which microbial contamination can affect product quality and manufacturing consistency. Mycoplasma testing is therefore incorporated into quality assurance activities at multiple stages of biological development and production. Manufacturers increasingly evaluate raw materials, cell banks, working cell cultures, and production intermediates to identify potential contamination risks. Testing institutions play an important role by providing specialized analytical services to pharmaceutical companies and research organizations. The need to investigate contamination events and document testing outcomes is creating recurring demand for reliable detection kits.
Restraint
"Analytical limitations and validation requirements increase testing complexity."
The Mycoplasma Detection Kit Market faces restraints associated with analytical sensitivity, specificity, and the need to validate testing procedures across different biological samples. Mycoplasmas represent a diverse group of microorganisms, and detection systems must recognize relevant species without producing misleading results from unrelated biological material. A testing method that performs effectively with one cell culture or sample matrix may require additional suitability assessment before being applied to another. Pharmaceutical quality control laboratories must establish that their selected methods can identify contamination at appropriate detection levels and produce consistent results. These requirements increase the technical effort involved in introducing new testing products, particularly when laboratories transition from established culture-based procedures to rapid molecular or immunological methods.
Another restraint involves the difference between detecting microbial genetic material and confirming the presence of viable organisms. Nucleic acid amplification methods can identify mycoplasma DNA, but the detection of genetic material does not necessarily establish whether the detected organisms remain viable. This distinction can become important when investigating contamination events, evaluating treatment effectiveness, and determining the suitability of biological production materials. Laboratories may therefore need complementary analytical procedures and additional interpretation steps. Traditional culture-based testing remains relevant for certain investigations, despite requiring observation periods of up to 28 days. Maintaining established methods alongside faster alternatives can increase laboratory operating complexity and testing expenditure.
Opportunity
"Expanding biologics production creates opportunities for advanced contamination screening."
The expansion of biologics and advanced therapeutic manufacturing represents a significant opportunity for the Mycoplasma Detection Kit Market. Pharmaceutical organizations are increasing their involvement in monoclonal antibody production, recombinant proteins, vaccines, and cell-based therapeutic development. These manufacturing activities rely on biological materials that require consistent contamination monitoring throughout development and production. Mycoplasma detection is particularly important because contamination can affect cell growth, metabolic activity, product characteristics, and manufacturing consistency. Testing procedures may be required at multiple stages, including cell bank qualification, raw material assessment, production monitoring, and final quality evaluation. This creates recurring demand for detection kits that can support reliable analytical performance across different production environments.
The increasing adoption of rapid molecular methods offers another commercial opportunity. Traditional culture-based procedures can require up to 28 days, whereas validated nucleic acid amplification methods can provide results in less than 1 day under appropriate conditions. This difference creates opportunities for manufacturers offering products that support faster contamination investigations and more efficient laboratory scheduling. Testing institutions can expand their service portfolios by incorporating validated rapid screening procedures, while pharmaceutical companies can evaluate these technologies for suitable in-process testing applications. The development of methods capable of recognizing more than 100 mollicute species is particularly important for laboratories seeking broad detection coverage. Improvements in assay design, reagent stability, and sample preparation are expected to strengthen product differentiation.
Challenge
"Maintaining detection accuracy across diverse biological samples remains challenging."
The Mycoplasma Detection Kit Market faces technical challenges associated with detecting diverse mycoplasma species in different biological sample environments. Cell cultures, biological manufacturing intermediates, serum-containing preparations, and clinical specimens can contain substances that interfere with analytical procedures. Sample preparation therefore plays an important role in determining the reliability of the final result. Laboratories must consider potential inhibitors, background signals, sample concentration, and the characteristics of the target organism. Methods intended to recognize more than 100 mollicute species require appropriate validation to demonstrate their coverage and analytical performance. Differences in detection limits and assay design can also make it difficult to compare results generated by separate testing platforms.
Regulatory compliance and method validation create additional challenges for manufacturers and end users. Testing laboratories must demonstrate that their procedures are suitable for the intended sample type and capable of identifying relevant contamination within defined analytical limits. Pharmaceutical organizations must maintain documented procedures, appropriate controls, qualified equipment, and traceable testing records. Changes in analytical technology may require bridging studies or additional validation before results can replace those obtained through established procedures. The relationship between nucleic acid detection and organism viability also requires careful interpretation. A positive molecular result may require further investigation, especially when laboratories are evaluating previously treated materials or determining the significance of residual genetic material.
Segmentation Analysis
Download Free sample to learn more about this report.
By Types
Colloidal Gold Type: Colloidal Gold Type products represent approximately 43% of the estimated product mix in the Mycoplasma Detection Kit Market. These products use colloidal gold particles as visible detection labels within an appropriate immunochromatographic assay configuration. Their main commercial advantage is the potential to provide rapid, straightforward result interpretation without requiring the same laboratory infrastructure as certain instrument-dependent analytical methods. The format can be useful in screening environments where ease of operation, sample handling, and shorter testing workflows are important. However, the detection capability depends on the biological target, antibody design, sample composition, and analytical sensitivity of the individual product. Mycoplasma contamination testing in cell culture and pharmaceutical manufacturing requires methods validated for the relevant organisms and sample types.
Enzyme Linked Immunosorbent: Enzyme Linked Immunosorbent products account for an estimated 57% of the product mix, making this the leading category under the market segmentation scenario. These products use enzyme-linked antigen-antibody reactions to generate measurable signals that indicate the presence of a target biological analyte. ELISA-based procedures are established across laboratory environments because they can support standardized sample processing, controlled reaction conditions, and comparative result evaluation. Their suitability depends on whether the assay is designed to identify relevant mycoplasma antigens or antibodies and whether the intended application involves clinical investigation or contamination monitoring. In pharmaceutical and biotechnology environments, laboratories must confirm that an immunoassay is appropriate for the specific contamination-control requirement.
By Applications
Hospital: Hospital applications account for an estimated 32% of the Mycoplasma Detection Kit Market. Hospitals require reliable testing capabilities for selected clinical investigations, microbiological evaluation, and laboratory-supported patient care. Mycoplasma-related testing can involve different organisms and clinical sample types, making assay selection dependent on the intended diagnostic question. Certain clinical investigations focus on Mycoplasma pneumoniae, while biological research and pharmaceutical quality control involve other mycoplasma species associated with cell culture contamination. Hospitals therefore require products with clearly defined analytical targets, suitable sample compatibility, and reliable result interpretation. Rapid screening formats may support selected testing requirements, whereas ELISA-based procedures can provide structured immunological assessment when clinically appropriate.
Clinics: Clinics represent approximately 22% of application demand under the estimated segmentation distribution. Their testing requirements are influenced by patient volume, available laboratory infrastructure, sample handling capabilities, and the need for timely clinical investigations. Depending on the clinical indication, clinics may use suitable immunological screening products or refer specimens to specialized testing facilities for more advanced analysis. Colloidal Gold Type products can be relevant where a validated rapid immunochromatographic test is available for the intended target, while Enzyme Linked Immunosorbent formats may support structured laboratory testing. Clinical use must distinguish between tests designed for detecting human immune responses and methods intended to identify mycoplasma contamination in cell cultures. These are not interchangeable applications.
Testing Institutions: Testing Institutions represent the leading application category, accounting for approximately 46% of total application demand. These organizations include specialized laboratories and analytical service providers involved in microbiological testing, pharmaceutical quality assurance, biotechnology research support, and biological sample evaluation. Their operations frequently involve multiple sample types and different analytical requirements, creating demand for reliable detection kits with established performance characteristics. Testing institutions are particularly important in pharmaceutical manufacturing because mycoplasma contamination can compromise cell culture materials and biological production batches. Laboratories may use validated molecular methods, culture-based procedures, and appropriate immunological assays depending on the target and purpose of testing.
Regional Outlook
Download Free sampleto learn more about this report.
North America
North America represents the largest regional market for mycoplasma detection kits, accounting for an estimated 34% of global demand. The United States contributes substantially through its pharmaceutical manufacturing infrastructure, biotechnology research organizations, vaccine production facilities, and specialized testing laboratories. The region has a strong presence of companies involved in biological product development, cell culture research, and advanced therapeutic manufacturing. These activities require systematic monitoring of biological materials to identify potential microbial contamination. Pharmaceutical manufacturers conduct testing across multiple production stages, including cell bank qualification, raw material assessment, and manufacturing quality control. The availability of specialized laboratories and trained analytical personnel supports the adoption of Colloidal Gold Type and Enzyme Linked Immunosorbent products for suitable testing requirements. Established distribution networks also improve the availability of laboratory reagents and detection products.
Regional demand is further supported by the growing use of molecular testing and rapid contamination screening in biological manufacturing. Conventional mycoplasma culture procedures can require up to 28 days, encouraging manufacturers to evaluate appropriately validated alternative analytical methods. United States laboratories are increasingly investing in automated testing, sample preparation, and analytical systems that can improve operational efficiency. Canada contributes through its biotechnology research institutions, pharmaceutical development activities, and specialized laboratory service providers. Research organizations are also expanding work involving cell-based therapies and advanced biological materials, increasing the importance of dependable contamination monitoring. The presence of established suppliers, including GeneCopoeia, Inc., InvivoGen, Lonza, and Abcam, supports the regional competitive environment. Continued investment in biologics and laboratory quality assurance is expected to sustain North American market leadership through 2035.
Europe
Europe accounts for approximately 26% of the global Mycoplasma Detection Kit Market and represents an established center for pharmaceutical manufacturing, biotechnology research, and laboratory quality control. Germany, the United Kingdom, France, Switzerland, and the Netherlands contribute through their pharmaceutical industries, research institutions, and specialized biological testing organizations. The region has an established regulatory and pharmaceutical quality environment that places considerable emphasis on microbial contamination monitoring. Biological manufacturing facilities require suitable testing procedures to evaluate cell substrates, production materials, and biological preparations. Mycoplasma detection is particularly important in cell-based production because contamination can affect product quality and manufacturing consistency. Testing institutions and pharmaceutical laboratories therefore require reliable kits that offer appropriate analytical performance and compatibility with validated testing procedures.
European demand is also influenced by developments in advanced therapeutic manufacturing and alternative microbiological testing methods. Pharmaceutical organizations are increasingly evaluating nucleic acid amplification technologies that can provide results in less than 1 day under appropriate validated conditions, compared with conventional culture procedures requiring up to 28 days. Germany contributes through its established pharmaceutical and biotechnology manufacturing base, while the United Kingdom supports market development through academic research and specialized analytical laboratories. France and Switzerland maintain important positions in biological research and pharmaceutical innovation. European laboratories are also focusing on documentation, assay suitability, analytical controls, and testing consistency. Manufacturers supplying Colloidal Gold Type and Enzyme Linked Immunosorbent products must address the different requirements of clinical laboratories and pharmaceutical quality control facilities. Continued investment in biologics, vaccine research, and advanced laboratory infrastructure is expected to support regional expansion.
Asia-Pacific
Asia-Pacific accounts for approximately 29% of the global Mycoplasma Detection Kit Market and is expected to register the fastest regional growth, with a projected CAGR of 10.7% during 2026–2035. China, India, Japan, South Korea, and Australia represent important demand centers because of their expanding pharmaceutical industries, biotechnology manufacturing capacity, and increasing investment in biomedical research. The region is experiencing growing development of biologics, biosimilars, vaccines, and cell-based therapeutic products. These manufacturing activities require appropriate contamination monitoring throughout biological production and laboratory testing. Research institutions and testing organizations are also increasing their involvement in cellular research and microbiological analysis. The expansion of pharmaceutical production facilities is encouraging demand for dependable detection products and specialized laboratory consumables.
China contributes through its growing biotechnology industry, vaccine manufacturing activities, and increasing pharmaceutical research capabilities. India is emerging as an important market because of its established pharmaceutical production sector and expanding contract research and manufacturing ecosystem. Japan and South Korea contribute through advanced life sciences research, laboratory automation, and specialized biological development programs. Australia supports regional activity through its biotechnology research infrastructure and pharmaceutical quality assurance services. Laboratories across the region are increasingly evaluating rapid testing technologies to improve contamination investigation timelines. Validated nucleic acid amplification methods capable of delivering results within 1 day provide an important alternative to extended culture-based procedures. Manufacturers can strengthen regional opportunities through localized distribution, technical assistance, and products designed for different laboratory requirements. Expanding biologics production and improving laboratory infrastructure are expected to maintain Asia-Pacific's position as the fastest-growing geographical market.
Rest of the World
The Rest of the World represents approximately 11% of the global Mycoplasma Detection Kit Market and includes Latin America, the Middle East, and Africa. Regional demand is developing as healthcare organizations, pharmaceutical manufacturers, and research institutions increase their investment in laboratory infrastructure and biological testing capabilities. Brazil and Mexico represent important Latin American markets because of their pharmaceutical industries, academic research facilities, and expanding healthcare laboratory networks. The increasing importance of vaccine production, biological product quality, and microbiological testing is encouraging the adoption of reliable contamination detection products. Hospitals and specialized testing institutions require suitable analytical solutions for different clinical and laboratory applications. Product availability is influenced by international distribution networks, laboratory procurement practices, and the presence of trained personnel.
The Middle East and Africa are also developing opportunities through investments in pharmaceutical manufacturing, biotechnology research, and healthcare modernization. Saudi Arabia and the United Arab Emirates are strengthening their healthcare and life sciences infrastructure, while South Africa represents an important center for specialized laboratory services and biomedical research in Africa. Demand for mycoplasma detection kits is influenced by the expansion of biological research, vaccine development, and pharmaceutical quality assurance activities. Laboratories may initially rely on established testing procedures before gradually introducing faster analytical technologies. Colloidal Gold Type products can address suitable rapid-screening requirements, while Enzyme Linked Immunosorbent products support structured laboratory testing. Improvements in research funding, technical training, and laboratory distribution are expected to support gradual market development across this geographical segment.
List of Top Mycoplasma Detection Kit Companies
- GeneCopoeia, Inc.
- InvivoGen
- Captivate Bio
- Creative Diagnostics
- SouthernBiotech
- Lonza
- GenWay Biotech, Inc.
- Abcam
- R&D Systems
- MyBioSource.com
- Novus Biologicals
- viva Systems Biology
- lifeSnan RioSciences
Top 2 Companies Market Share
Lonza: Lonza maintains an important position in the mycoplasma testing industry through its established biological manufacturing support, analytical testing capabilities, and specialized contamination detection solutions. Its MycoAlert product portfolio is associated with rapid mycoplasma detection in cell culture applications and supports laboratories seeking alternatives to lengthy conventional culture procedures. The company serves pharmaceutical manufacturers, biotechnology organizations, and research institutions that require dependable contamination monitoring. Its experience in biological manufacturing and quality control provides a strong foundation for addressing specialized testing requirements. Lonza's analytical solutions are relevant to laboratories investigating cell culture contamination, evaluating biological materials, and maintaining production quality.
GeneCopoeia, Inc.: GeneCopoeia, Inc. participates in the Mycoplasma Detection Kit Market through its life science research product portfolio and laboratory solutions for molecular biology and cell-based investigations. The company serves academic laboratories, biotechnology researchers, and pharmaceutical organizations involved in genetic research and cellular experimentation. Reliable contamination screening is important for these customers because mycoplasma contamination can influence experimental reproducibility and cellular characteristics. The company's presence in molecular biology and research consumables provides opportunities to address laboratory requirements associated with cell culture quality assurance. Its competitive relevance is supported by the growing need for dependable testing materials and accessible research products.
Investment Analysis
Investment in the Mycoplasma Detection Kit Market is increasingly focused on improving analytical sensitivity, reducing testing turnaround times, and strengthening contamination monitoring across pharmaceutical and biotechnology manufacturing. Manufacturers are directing resources toward improved immunoassay reagents, rapid screening formats, molecular detection technologies, and automated sample processing capabilities. Enzyme Linked Immunosorbent products provide opportunities for standardized laboratory testing, while Colloidal Gold Type products address suitable rapid-screening requirements. Investment in reagent stability, assay specificity, reference controls, and manufacturing consistency is becoming increasingly important because laboratories require dependable performance across repeated testing procedures. The growing importance of biological quality control is also encouraging specialized testing institutions to expand their analytical capabilities. Pharmaceutical manufacturers increasingly require testing procedures covering cell banks, biological starting materials, intermediate production samples, and finished products. Traditional culture procedures can require up to 28 days, creating investment opportunities for validated analytical technologies capable of shortening testing timelines.
Geographical expansion is another important investment priority, particularly in Asia-Pacific, where the market is projected to expand at a 10.7% CAGR during 2026–2035. China, India, Japan, and South Korea offer opportunities through expanding pharmaceutical production, biotechnology research, and advanced healthcare development. Companies are evaluating distribution partnerships, regional laboratory support, and improvements in product accessibility to strengthen their presence across emerging markets. North America and Europe remain important investment destinations because of their established pharmaceutical manufacturing infrastructure and specialized testing capabilities. Investment in automated detection platforms, molecular sample preparation, and integrated quality control procedures is also creating opportunities for companies serving biologics and cell-based therapeutic manufacturers. The projected 8.9% overall market CAGR through 2035 provides a favorable commercial environment for suppliers focusing on dependable analytical performance, validated testing procedures, and application-specific product development.
New Product Development
New product development in the Mycoplasma Detection Kit Market is increasingly focused on improving detection sensitivity, simplifying laboratory procedures, and reducing the time required to investigate contamination. Manufacturers are refining immunoassay technologies to improve antigen recognition, antibody specificity, signal consistency, and reagent stability. Enzyme Linked Immunosorbent products are being developed with standardized assay components and improved controls to support repeatable laboratory procedures. Colloidal Gold Type products are benefiting from improvements in detection labels, membrane characteristics, sample compatibility, and visual result interpretation. These developments are important for laboratories that require convenient screening products without compromising the analytical requirements of their intended applications. Product manufacturers are also focusing on packaging stability and simplified operating instructions to support consistent use across different laboratory environments.
Another important development area involves the integration of automated molecular testing, rapid sample preparation, and improved analytical controls. Modern nucleic acid amplification systems can provide mycoplasma detection results in less than 1 day when appropriately validated, compared with traditional culture methods requiring up to 28 days. Although these molecular systems represent a distinct technology category from the two supplied product segments, their development is influencing the broader competitive environment for detection kits. Manufacturers are increasingly emphasizing compatibility with different biological sample types, broad organism coverage, and reliable interpretation of positive and negative controls. Research into DNA and RNA detection, quantitative amplification, and automated analytical procedures is also supporting innovation. Continued development of more stable reagents, reproducible immunological assays, and convenient screening formats is expected to strengthen the product portfolios of companies serving hospitals, clinics, and testing institutions.
Five Recent Developments
- February 2024 – Thermo Fisher Scientific expands biosafety testing: The company's PPD clinical research business expanded its GMP laboratory services in Middleton, Wisconsin, to include mycoplasma and additional biosafety testing. The expansion strengthened specialized analytical support for biopharmaceutical customers.
- May 2024 – Rapid mycoplasma testing partnership strengthens implementation: bioMérieux and AnaBioTec established a partnership to support the implementation and validation of rapid BIOFIRE Mycoplasma testing for pharmaceutical, biopharmaceutical, and cell and gene therapy applications in Europe. The collaboration addressed validation requirements associated with faster molecular testing.
- September 2024 – bioMérieux and Bionique expand validation support: The companies introduced access to product-specific method validation services for the BIOFIRE Mycoplasma testing system. Bionique's more than 30 years of specialized testing experience supported implementation and regulatory compliance activities.
- October 2025 – Lonza announces Redberry acquisition: Lonza signed an agreement to acquire Redberry SAS to expand its rapid microbiology testing capabilities. The transaction included the Red One solid-phase cytometry platform and was completed on January 30, 2026, strengthening its broader pharmaceutical quality control portfolio.
- April 2026 – bioMérieux launches BIOFIRE SPOTFIRE for pharmaceutical testing: The company introduced a molecular testing solution designed for pharmaceutical industry applications. The platform builds on its existing BIOFIRE technology and targets faster mycoplasma detection and improved contamination-control workflows in biopharmaceutical manufacturing.
Report Coverage
The Mycoplasma Detection Kit Market Report provides a structured assessment of global industry development, product innovation, competitive positioning, and future demand throughout the 2026–2035 forecast period. The analysis considers historical market development from 2021 to 2024 and uses 2025 as the base year for evaluating future opportunities. Market segmentation covers 2 product categories, Colloidal Gold Type and Enzyme Linked Immunosorbent, and 3 applications, Hospital, Clinics, and Testing Institutions. The report evaluates differences in analytical principles, testing procedures, sample compatibility, and laboratory requirements across these categories. It also examines the influence of pharmaceutical manufacturing, biologics development, vaccine production, cell culture research, and contamination-control requirements on market adoption. Regional coverage includes North America, Europe, Asia-Pacific, and the Rest of the World, with estimated regional shares of 34%, 26%, 29%, and 11%, respectively, totaling exactly 100%.
The competitive assessment covers 13 companies, including GeneCopoeia, Inc., InvivoGen, Captivate Bio, Creative Diagnostics, SouthernBiotech, Lonza, GenWay Biotech, Inc., Abcam, R&D Systems, MyBioSource.com, Novus Biologicals, viva Systems Biology, and lifeSnan RioSciences. The report examines product portfolios, analytical technologies, manufacturing capabilities, distribution strategies, and research-oriented product development. Market dynamics analysis evaluates contamination-control requirements, analytical validation, testing turnaround times, and the expansion of biological manufacturing. Investment opportunities are assessed across reagent development, improved immunoassay technologies, rapid screening solutions, and automated laboratory testing. The report also considers emerging developments in molecular detection, regulatory expectations, and specialized laboratory services. North America is identified as the leading regional market with an estimated 34% share, while Asia-Pacific is projected to record the fastest growth at 10.7% CAGR during 2026–2035. These assessments provide a comprehensive understanding of industry opportunities, technological developments, application requirements, and competitive conditions shaping the Mycoplasma Detection Kit Market.
| REPORT COVERAGE | DETAILS |
|---|---|
|
Market Size Value In |
US$ 5921.31 Million in 2026 |
|
Market Size Value By |
US$ 12009.05 Million by 2035 |
|
Growth Rate |
CAGR of 8.9 % from 2026 to 2035 |
|
Forecast Period |
2026 to 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
2021-2024 |
|
Regional Scope |
Global |
|
Segments Covered |
Type and Application |
Related Reports
-
What will be the projected value of Mycoplasma Detection Kit Market by 2035?
The Mycoplasma Detection Kit Market is projected to reach USD 12009.05 Million by 2035, expanding at a steady pace during the forecast period. Market growth is supported by rising demand, technological advancements, and increasing adoption across major end-use industries worldwide.
-
What is the expected CAGR of the Mycoplasma Detection Kit Market during 2026-2035?
The Mycoplasma Detection Kit Market is expected to grow at a CAGR of 8.9% during the forecast period from 2026 to 2035.
-
Which companies are leading the Mycoplasma Detection Kit Market?
Key players in the Mycoplasma Detection Kit Market market include GeneCopoeia, Inc., InvivoGen, Captivate Bio, Creative Diagnostics, SouthernBiotech, Lonza, GenWay Biotech, Inc., Abcam, R&D Systems, MyBioSource.com, Novus Biologicals, viva Systems Biology, lifeSnan RioSciences
-
How large was the Mycoplasma Detection Kit Market in 2025?
The Mycoplasma Detection Kit Market was valued at USD 5437.38 Million in 2025, reflecting strong demand and continued adoption across major industries.